Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | PNMT | P11086 | 2/20 | 0.58 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.48 |
| ▸ | HTR3B | O95264 | 3/20 | 0.48 |
| ▸ | HTR3A | P46098 | 3/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11530544 | 0.87 | TSHR (0.62) | TSHRRECQLPNMTPYCR1TAAR1 | |
| SCHEMBL2436 | 0.83 | — | — | |
| SCHEMBL5733314 | 0.83 | PNMT (0.60) | TSHRRECQLPNMTPYCR1TAAR1 | |
| SCHEMBL29353832 | 0.83 | — | — | |
| SCHEMBL30798978 | 0.82 | TAAR1 (0.66) | TSHRRECQLPNMTPYCR1TAAR1 | |
| SCHEMBL8290710 | 0.82 | TAAR1 (0.66) | TSHRRECQLPNMTPYCR1TAAR1 | |
| SCHEMBL10780774 | 0.82 | TSHR (0.56) | TSHRRECQLPNMTPYCR1TAAR1 | |
| SCHEMBL11028540 | 0.81 | PNMT (0.58) | TSHRRECQLPNMTPYCR1TAAR1 | |
| SCHEMBL1001013 | 0.81 | PNMT (0.58) | TSHRRECQLPNMTPYCR1TAAR1 | |
| SCHEMBL30093221 | 0.79 | PYCR1 (0.67) | TSHRRECQLPNMTPYCR1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382945-A1 | THERAPEUTIC AGENTS AND METHODS | POP TEST ONCOLOGY LLC (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382945-A1 | THERAPEUTIC AGENTS AND METHODS | POP TEST ONCOLOGY LLC (US) | 2023-11-30 | — | — | US | disclosed |
| US-11702443-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702443-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702443-B2 | Therapeutic agents and methods | NR1H4, NR3C1, NR3C2 | TSHR 323/4885RECQL 4318/4885PNMT 3089/4885 |
| US-20230382945-A1 | THERAPEUTIC AGENTS AND METHODS | NR1H4, NR3C1, NR3C2 | TSHR 323/4885RECQL 4318/4885PNMT 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.